What Is Antidepressant Discontinuation Syndrome?
Antidepressant discontinuation syndrome (ADS) is a cluster of symptoms that can occur when an antidepressant — particularly an SSRI or SNRI — is stopped abruptly or the dose is reduced too quickly. It affects approximately 20–40% of patients who stop these medications suddenly.
Symptoms typically begin within 2–4 days of stopping and include:
- FINISH mnemonic: Flu-like symptoms, Insomnia, Nausea, Imbalance/dizziness, Sensory disturbances (electric shock sensations called "brain zaps"), Hyperarousal/[anxiety](/conditions/anxiety)
- Irritability and mood changes
- Vivid dreams or nightmares
- Diarrhea
Discontinuation syndrome is not the same as relapse of [depression](/conditions/depression) — it is a physiological response to the sudden removal of a drug that the brain has adapted to. Symptoms typically resolve within 1–2 weeks if the medication is restarted or tapered slowly.
Which Antidepressants Cause the Most Discontinuation Symptoms?
| Antidepressant | Discontinuation Risk | Reason |
|---|---|---|
| Paroxetine (Paxil) | Very high | Shortest half-life of [SSRIs](/drug-classes/ssris); strong anticholinergic effects |
| Venlafaxine (Effexor) | Very high | Short half-life; potent SNRI |
| Duloxetine (Cymbalta) | High | Short half-life SNRI |
| Sertraline (Zoloft) | Moderate | Intermediate half-life |
| Escitalopram (Lexapro) | Moderate | Intermediate half-life |
| Citalopram (Celexa) | Moderate | Intermediate half-life |
| Fluoxetine (Prozac) | Low | Very long half-life (4–6 days); self-tapering |
| Bupropion (Wellbutrin) | Low | Different mechanism; less serotonergic |
Safe Tapering Schedules
The general principle is to reduce the dose by no more than 10–25% every 2–4 weeks. Slower tapers are needed for longer duration of use, higher doses, and drugs with short half-lives (paroxetine, venlafaxine).
Sertraline (Zoloft) Taper Example
Starting dose: 100 mg/day
- Weeks 1–2: 75 mg/day
- Weeks 3–4: 50 mg/day
- Weeks 5–6: 25 mg/day
- Week 7: Discontinue
Venlafaxine (Effexor) Taper Example (Requires Slower Taper)
Starting dose: 150 mg/day
- Weeks 1–2: 112.5 mg/day
- Weeks 3–4: 75 mg/day
- Weeks 5–6: 37.5 mg/day
- Weeks 7–8: 37.5 mg every other day
- Week 9: Discontinue
For paroxetine and venlafaxine, some patients require an even slower taper — reducing by as little as 5–10% per month using liquid formulations or compounded preparations.
Fluoxetine (Prozac): Often No Taper Needed
Fluoxetine has a very long half-life (4–6 days for the parent drug, 4–16 days for its active metabolite nor[fluoxetine](/drugs/fluoxetine)). This means the drug effectively tapers itself over 1–2 months after the last dose. For most patients, abrupt discontinuation of fluoxetine does not cause significant discontinuation symptoms. However, a brief taper is still recommended for patients on high doses (>40 mg) or with a history of discontinuation symptoms.
Distinguishing Discontinuation Syndrome from Relapse
This distinction is clinically important:
- Discontinuation syndrome — begins within 2–4 days of stopping; includes physical symptoms (dizziness, nausea, brain zaps); resolves within 1–2 weeks; responds to restarting the medication
- Relapse of depression — begins 2–4 weeks or more after stopping; primarily mood symptoms (persistent sadness, hopelessness, loss of interest); does not resolve spontaneously; requires treatment
When Should You Stop an Antidepressant?
The decision to stop an antidepressant should be made with your prescriber. General guidelines suggest:
- First episode of depression: continue for at least 6–12 months after remission
- Second episode: continue for at least 2 years
- Three or more episodes: consider indefinite maintenance therapy
- Never stop during a period of high stress or life change
- Ensure you have a follow-up appointment scheduled within 2–4 weeks of stopping
References
- Fava GA, et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72-81.
- Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6(6):538-546.
- Schatzberg AF, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry. 2006;67(Suppl 4):27-30.
Save up to 80% on this medication
Use a free RxGo discount card at 67,000+ pharmacies — no sign-up, no insurance needed.
About the Author
James Okafor, RPh, MBA
Registered Pharmacist & Health Economics Writer
James Okafor is a registered pharmacist with over 12 years of experience in retail and clinical pharmacy settings. He holds an MBA with a focus on healthcare management and specializes in translating complex drug pricing, formulary, and insurance coverage topics into clear, actionable guidance for patients. Before joining RxGuide, James worked as a clinical pharmacist at a regional hospital system and as a pharmacy benefits consultant for a national PBM. His writing focuses on cost transparency, generic alternatives, and helping patients navigate the U.S. prescription drug system.
View full profile on our Editorial Team page →Get the RxGo app — free prescription discounts on the go
Works at 67,000+ pharmacies · No membership needed